FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

1. Name and Address of Reporting Person* BERTHELSEN SPENCER R			2. Issuer Name and Ticker or Trading Symbol IONIS PHARMACEUTICALS INC [IONS]	5. Rela (Check	rson(s) to Issuer		
					Director		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 07/01/2019	1	Officer (give title below)	Other (specify below)	
C/O IONIS PHARMACEUTICALS, INC.			07/01/2015				
2855 GAZELLE COURT							
			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicab Line)			
(Street)				X	Form filed by One Rep	oorting Person	
CARLSBAD	CA	92010			Form filed by More that Person	an One Reporting	
(City)	(State)	(Zip)					

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

		•			-		•			
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)					5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	07/01/2019	07/01/2019	M ⁽¹⁾		666(1)	A	\$ <mark>0</mark>	94,760	D	
Common Stock	07/01/2019	07/01/2019	M ⁽¹⁾		667(1)	A	\$ <mark>0</mark>	95,427	D	
Common Stock	07/02/2019	07/02/2019	M ⁽¹⁾		889(1)	A	\$ <mark>0</mark>	96,316	D	
Common Stock	07/03/2019	07/03/2019	M ⁽¹⁾		667(1)	A	\$ <mark>0</mark>	96,983	D	
Common Stock								70 ⁽²⁾	I	By daughter

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

I															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		5. Numl of Derivat Securit Acquire (A) or Dispose (D) (Ins 4 and 5	Expiration Date (Month/Day/Year) irities iried osed of instr. 3,			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Restricted Stock Units	(3)	07/01/2019	07/01/2019	М			666	(4)	(4)	Common Stock	666	\$0	0	D	
Restricted Stock Units	(3)	07/01/2019	07/01/2019	М			667	(4)	(4)	Common Stock	667	\$0	666	D	
Restricted Stock Units	(3)	07/02/2019	07/02/2019	М			889	(4)	(4)	Common Stock	889	\$0	2,666	D	
Restricted Stock Units	(3)	07/03/2019	07/03/2019	М			667	(4)	(4)	Common Stock	667	\$0	1,333	D	
Restricted Stock Units	(3)	07/01/2019	07/01/2019	A		7,110		(5)	(5)	Common Stock	7,110	\$0	7,110	D	
Director Stock Option (right to buy)	\$64.8	07/01/2019	07/01/2019	A		16,000		07/01/2020 ⁽⁶⁾	06/30/2029 ⁽⁶⁾	Common Stock	16,000	\$0	16,000	D	

Explanation of Responses:

1. Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards.

2. The reporting person disclaims beneficial ownership of all securities held by his daughter, and this report should not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

3. Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

4. Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

5. Grant of July 1, 2019 to reporting person of Restricted Stock Unit Award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on July 1, 2020. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on July 1, 2023. The RSU is vested as to 0 shares on July 1, 2019.

6. Grant of July 1, 2019 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in four equal annual installments, the first installment vesting on July 1, 2020. The option shall be fully vested and exercisable on July 1, 2023. The option is exercisable to 0 shares on July 1, 2019.

Remarks:

/s/Patrick R. O'Neil, attorney-in-07/03/2019

fact ** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.